Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration. 1999

O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
Department of Vitreoretinal Surgery, SSK Eye Hospital Akara, Turkey.

OBJECTIVE To assess aqueous and vitreous humour ciprofloxacin concentrations following oral and topical administration of ciprofloxacin in patients with non-inflamed cornea and an intact crystalline lens, and to compare the concentrations of the drug given by either route. METHODS In this prospective study, 34 patients undergoing pars plana vitrectomy for various ocular pathologies were divided into two groups. Eighteen patients received 2 drops of 0.3% ophthalmic solution of ciprofloxacin every 30 min for 3 h and then every 60 min for the next 3 h, and 16 patients received a single oral dose of 1000 mg ciprofloxacin 6 h before surgery. The aqueous and vitreous humour samples were simultaneously harvested after oral or topical administration during pars plana vitrectomy to assess penetration of the drug. These samples were assayed for ciprofloxacin concentrations by a method described previously by us using high-performance liquid chromatography. RESULTS The aqueous and vitreous humour levels of ciprofloxacin were 0.59 +/- 0.06 microgram/ml (mean +/- SEM) and 0.64 +/- 0.06 microgram/ml after oral and 0.44 +/- 0.07 microgram/ml and 0.22 +/- 0.04 microgram/ml after topical ciprofloxacin administration, respectively. Aqueous humour levels were not statistically significantly different following oral and topical administration (p = 0.069). However, the vitreous level of the drug after oral administration was significantly higher than that after topical administration (p < 0.001). CONCLUSIONS Ocular bioavailability of ciprofloxacin in aqueous humour following oral and topical administration is found to be similar when the drug was applied as described above. Penetration of ciprofloxacin into vitreous humour is less than that into aqueous humour after topical administration.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents

Related Publications

O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
February 2003, Clinical & experimental ophthalmology,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
January 1998, Retina (Philadelphia, Pa.),
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
December 2012, Acta ophthalmologica,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
July 1990, The Journal of antimicrobial chemotherapy,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
August 1996, Experimental eye research,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
January 2007, European journal of ophthalmology,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
February 1970, The British journal of ophthalmology,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
December 1998, Acta ophthalmologica Scandinavica,
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
January 1999, Retina (Philadelphia, Pa.),
O Cekiç, and C Batman, and U Yasar, and N E Başci, and A Bozkurt, and S O Kayaalp
January 2008, Archives of ophthalmology (Chicago, Ill. : 1960),
Copied contents to your clipboard!